Sunday 11 October 2026
Export all RLYB data to Excel Powerpack
Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
17.02
0.03
+0.18%
Follow RLYB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
33.34 | 36.02 | 59.48 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(3.43) | (6.61) | (6.40) | — | |
P/B ratio |
0.36 | 0.53 | 1.02 | — | |
Price to Tangible BV |
0.36 | 0.53 | 1.02 | — | |
EV/Sales |
(54.67) | (27.77) | 4.94 | — | |
EV/EBITDA |
0.95 | 0.71 | 0.00 | — | |
EV/Operating CF |
1.05 | 0.80 | (0.15) | — | |
EV/FCF |
1.05 | 0.80 | (0.15) | — | |
Quick Ratio |
13.13 | 12.96 | 11.30 | 26.03 | |
Current Ratio |
14.74 | 14.50 | 12.92 | 27.26 | |
Net Debt/EBITDA |
8.47 | 8.41 | 5.33 | 16.42 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.00 | |
Operating CF/Net income |
(0.41) | 0.80 | 0.96 | 1.05 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,954.25% | 1,646.40% | 1,354.25% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,412.26% | 1,341.89% | 2,865.09% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
493.87% | 348.65% | 289.15% | 0.00% | |
Graham Net Nets |
2.76 | 1.84 | 0.97 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(64.16%) | (28.80%) | (15.17%) | — | |
Free Cash Flow Yield |
(155.86%) | (96.55%) | (54.12%) | — | |
Revenue per Share |
0.04 | 0.04 | 0.04 | 0.00 | |
Operating CF per Share |
(1.16) | (0.83) | (1.40) | 8.06 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.16) | (0.83) | (1.40) | 8.06 | |
Cash per Share |
10.53 | 9.72 | 8.23 | 16.29 | |
Shareholders Equity per Share |
11.19 | 10.29 | 8.84 | 16.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.19 | 10.29 | 8.84 | 16.58 | |
Free Cash Flow |
(6.55) | (4.68) | (7.98) | 45.92 | |
Working Capital |
62.11 | 57.03 | 49.35 | 93.69 | |
Net Current Asset Value |
62.00 | 56.95 | 49.30 | 93.69 | |
EV/EBIT |
0.96 | 0.72 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Payables |
0.43 | 0.20 | 0.67 | 0.48 | |
Average Assets |
73.33 | 65.18 | 56.23 | 74.53 | |
Average Common Equity |
66.93 | 59.81 | 52.18 | 70.23 |
Columns are period end dates